Study to Evaluate the Safety of Griffithsin in a Carrageenan Gel in Healthy Women

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

July 31, 2018

Study Completion Date

September 1, 2018

Conditions
HIV Infection
Interventions
DRUG

Griffithsin Gel

"Griffithsin Gel is a large biologic molecule that is intended for vaginal rather than systemic administration. In addition, Griffithsin Gel is being developed for the prevention of HIV infection and not as a therapeutic agent. The concentration of Griffithsin Gel associated with prevention of HIV in vitro and in vivo has been established in non-clinical studies (see Section 5). Studies have demonstrated that Griffithsin Gel is highly potent for HIV prevention and is effective at very low concentrations.~One 4 mL dose of PC-6500, designed to provide an adequate vaginal concentration of GRFT for the prevention of HIV, based on preclinical data, will be evaluated. Rising dose tolerance is not the goal of this study because GRFT is likely to be minimally absorbed systemically, if at all."

DRUG

Placebo Gel

Placebo Gel

Trial Locations (1)

10461

Albert Einstein College of Medicine, The Bronx

All Listed Sponsors
lead

Population Council

OTHER

NCT02875119 - Study to Evaluate the Safety of Griffithsin in a Carrageenan Gel in Healthy Women | Biotech Hunter | Biotech Hunter